达维塔保健 2024年度报告

☐ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the Fiscal Year Ended December 31, 2024or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ___________ to ___________Commission File Number: 1-14106 51-0354549 (I.R.S. Employer Identification No.) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the SecuritiesAct.Yes☐No☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of theExchange Act.Yes☐No☐ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was requiredto file such reports) and (2) has been subject to such filing requirements for the past 90 days.Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for suchshorter period that the registrant was required to submit such files).Yes☐No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "acceleratedfiler," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act: Large accelerated filer☐Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) ofthe Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessmentof the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its final report.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ExchangeAct).Yes☐No☐If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether financial statementsof the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis ofincentive-based compensation received by any of the registrant’s executive officers during the relevant recovery periodpursuant to §240.10D-1(b).☐As of June 30, 2024, the aggregate market value of the registrant's common stock outstanding held by non-affiliatesbased upon the closing price on the New York Stock Exchange was approximately $11.8 billion.As of January 31, 2025, the number of shares of the registrant’s common stock outstanding was approximately 80.0million shares. Documents incorporated by reference Portions of the registrant’s proxy statement for its 2025 annual meeting of stockholders are incorporated by referencein Part III of this Form 10-K. DAVITA INC.INDEX Page No. PART I. Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures 2245353555555 PART II. Item 5.Market for the Registrant's Common Equity, Related Stockholder Matters andIssuer Purchases of Equity Securities56Item 6.Reserved56Item 7.Management's Discussion and Analysis of Financial Condition and Results ofOperations57Item 7A.Quantitative and Qualitative Disclosures about Market Risk79Item 8.Financial Statements and Supplementary Data79Item 9.Changes in and Disagreements with Accountants on Accounting and FinancialDisclosure79Item 9A.Controls and Procedures80Item 9B.Other Information80Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections80 PART III. Item 10.Directors, Executive Officers and Corporate Governance81Item 11.Executive Compensation81Item 12.Security Ownership of Certain Beneficial Owners and Management and81 Related Stockholder MattersItem 13.Certain Relationships and Related Transactions, and Director Independence82Item 14.Principal Accounting Fees and Services82 PART IV. Item 15.Exhibits, Financial Statement Schedules83Item 16.Form 10-K Summary83 Exhibit Index1 of 4SignaturesS-1 PART I Item 1.Business Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similarterms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterlyreports on Form 10-